JP2024520142A - 乳癌を処置する方法 - Google Patents

乳癌を処置する方法 Download PDF

Info

Publication number
JP2024520142A
JP2024520142A JP2023574549A JP2023574549A JP2024520142A JP 2024520142 A JP2024520142 A JP 2024520142A JP 2023574549 A JP2023574549 A JP 2023574549A JP 2023574549 A JP2023574549 A JP 2023574549A JP 2024520142 A JP2024520142 A JP 2024520142A
Authority
JP
Japan
Prior art keywords
breast cancer
olaparib
treatment
patients
years
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023574549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520142A5 (https=
Inventor
フィールディング，アニトラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2024520142A publication Critical patent/JP2024520142A/ja
Publication of JP2024520142A5 publication Critical patent/JP2024520142A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2023574549A 2021-06-02 2022-05-31 乳癌を処置する方法 Withdrawn JP2024520142A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163195795P 2021-06-02 2021-06-02
US63/195,795 2021-06-02
PCT/EP2022/064697 WO2022253800A1 (en) 2021-06-02 2022-05-31 Methods of treating breast cancer

Publications (2)

Publication Number Publication Date
JP2024520142A true JP2024520142A (ja) 2024-05-21
JP2024520142A5 JP2024520142A5 (https=) 2025-06-09

Family

ID=82117716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574549A Withdrawn JP2024520142A (ja) 2021-06-02 2022-05-31 乳癌を処置する方法

Country Status (12)

Country Link
US (1) US20240269135A1 (https=)
EP (1) EP4346828A1 (https=)
JP (1) JP2024520142A (https=)
KR (1) KR20240016344A (https=)
CN (1) CN118139624A (https=)
AU (1) AU2022286616A1 (https=)
BR (1) BR112023025003A2 (https=)
CA (1) CA3220751A1 (https=)
CL (1) CL2023003533A1 (https=)
IL (1) IL308684A (https=)
MX (1) MX2023014420A (https=)
WO (1) WO2022253800A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu

Also Published As

Publication number Publication date
CA3220751A1 (en) 2022-12-08
MX2023014420A (es) 2024-04-23
CN118139624A (zh) 2024-06-04
WO2022253800A1 (en) 2022-12-08
US20240269135A1 (en) 2024-08-15
KR20240016344A (ko) 2024-02-06
BR112023025003A2 (pt) 2024-02-20
AU2022286616A1 (en) 2024-01-18
IL308684A (en) 2024-01-01
EP4346828A1 (en) 2024-04-10
CL2023003533A1 (es) 2024-06-28

Similar Documents

Publication Publication Date Title
Jiang et al. Chinese society of clinical oncology (CSCO) breast cancer guidelines 2022
Thomas et al. Invasive lobular breast cancer: A review of pathogenesis, diagnosis, management, and future directions of early stage disease
Benson et al. Early breast cancer
Gradishar et al. Breast cancer version 3.2014
Mowad et al. Does obesity have an effect on outcomes in triple-negative breast cancer?
Jwa et al. Locoregional recurrence by tumor biology in breast cancer patients after preoperative chemotherapy and breast conservation treatment
Edwards et al. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation
Tsakonas et al. c-MET as a biomarker in patients with surgically resected non-small cell lung cancer
Rubovszky et al. Systemic treatment of breast cancer. 1st Central-Eastern European professional consensus statement on breast cancer
Desai et al. Patterns of relapse in stage I–II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy
Yu et al. Cyclophosphamide-free adjuvant chemotherapy for ovarian protection in young women with breast cancer: a randomized phase 3 trial
Kim et al. Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
Dracham et al. Toxicity and clinical outcomes with definitive three-dimensional conformal radiotherapy (3DCRT) and concurrent cisplatin chemotherapy in locally advanced cervical carcinoma
Yu et al. Post-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity
Colonna et al. Analysis of risk of recurrence by subtype in≤ 1-cm breast tumors
Yuan et al. Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial
Arellano et al. Current status and future directions in unresectable stage III non-small cell lung cancer
Bychkovsky et al. Ductal Carcinoma In Situ
Marchetti et al. Letrozole in the management of advanced ovarian cancer: an old drug as a new targeted therapy
JP2024520142A (ja) 乳癌を処置する方法
Powell et al. Endometrial Cancer: Updates in Molecular Characterization and Treatment Opportunities
Psyrri Exceptional Response to Copanlisib in a Heavily Pretreated Patient WithPIK3CA-Mutated Metastatic Breast Cancer
Yariv et al. The Impact of Exogenous Estrogen Exposure on the Characteristics and Outcome of Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer
Pérez-García et al. Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
Edwards et al. Molecular Genetics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250529

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20260427